NattoPharma created the Vitamin K2 category, driving all research demonstrating bone- and heart-health benefits of MenaQ7® Vitamin K2 as MK-7. That research has the medical community conducting its own trials exploring K2 as a potential therapy.
Even more exciting is the widening examination of the K2 mechanism – specifically the activation of MGP – and how this impacts other systems.
Join NattoPharma for a must-attend Vitafoods Digital Week webinar where our experts will provide a new insight on our growing clinical evidence (20 published trials) and how that can lead to greater product opportunities.
